Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1).
about
The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data.Determination of the three-dimensional, solution-phase structure of the macrolide antibiotic oxolide in CD2Cl2 and D2O from NMR constraints.Investigational antimicrobial agents of 2013.In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogensCytochrome P450 Enzyme Metabolites in Lead Discovery and Development.The new macrolide antibiotics. Azithromycin and clarithromycin.In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycinClarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles.In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycinSusceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model.Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolideAntibiotic susceptibility of group A streptococci: a 6-year follow-up study.Macrolides in chronic inflammatory skin disorders.Pharmacokinetics of roxithromycin (RU 965).Ureaplasma urealyticum intrauterine infection: role in prematurity and disease in newbornsAntimicrobial therapy for the elderly patient.Antivirulence activity of azithromycin in Pseudomonas aeruginosaUsing erythromycin. Some helpful observations.The role of macrolides in noncystic fibrosis bronchiectasisIn vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia.Erythromycin shortens neutrophil survival by accelerating apoptosis.New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance.Effect of macrolide antibiotics on macrophage functions.Erythromycin-induced suppression of pulmonary antibacterial defenses. A potential mechanism of superinfection in the lung.Comparative in vitro activity of the new oral macrolide azithromycin.Delivery of erythromycin to subcutaneous tissues in rats by means of a trans-phase delivery system.A case of bovine mastitis caused by Listeria monocytogenes.Gynaecological tissue levels of azithromycin.Synthesis and antibacterial activity of novel 4''-O-carbamoyl erythromycin-A derivatives.Isolation and identification of a novel impurity of erythromycin A 9-oxime desosaminehydrazinium salt.Clinical efficacy and tolerance of two new macrolides, clarithromycin and josamycin, in the treatment of patients with acute exacerbations of chronic bronchitis.Increased use of erythromycin causes resistance in Haemophilus influenzae.Therapeutic effect of spiramycin in brucellosis
P2860
Q30577239-7CE22F9D-593F-485E-87B1-6115FCCF655BQ33207679-4EF86197-BBF8-4B81-9E90-47F142B8E8A8Q34375204-7FF6E211-6C26-4F99-B577-7C49C53FF442Q35111191-6D9B7705-ECE0-49C5-8ED3-81EBD733C400Q35194778-6F4B10D0-F12A-4E80-B57B-DD8A31D72B6BQ35229425-17015F0E-07EF-45A3-8963-2B26764AC69EQ35305599-4EC5AF6D-57DC-4826-9E3A-54FB3A9A0E29Q35466622-3E43F72E-7BBB-40A8-A324-6ACB2D256AC7Q35537259-777341B1-E52A-4556-B414-73BEE9D79B09Q35541132-29E2DED1-92DF-4CAA-9DF1-269141E3091AQ35562871-C3362D99-84EC-4083-8BD5-D79E44B34363Q35653665-1FFE1779-363C-4DE7-9E7F-DD6A1406B787Q35818190-2FF61B60-F243-4E67-859E-5854D0216C9AQ35997016-011DF315-168B-417A-8FF8-5FDCF4A9DE65Q36450885-4AB53E83-3AC8-47D2-B294-5DF69AB59F30Q36639538-E0F25B20-2F8F-4003-A6A1-5449F10D429BQ38006505-2889D17A-9BBB-4253-BF2C-05705C1B04ACQ38209321-709ADE36-FCAA-45FE-8311-FE5193FB947DQ38654187-1D54E47D-AB51-4D0A-A3B4-4F05A4ACA568Q38833477-5FB72172-9714-4519-A24A-0ACD7B28A8E2Q39478420-FECF50B0-48D3-40C9-BDF6-DFF105975641Q39779501-76ABFEDD-54B5-4416-BD99-81F7BEB63BF0Q39814794-1E4ECAF0-1E44-485C-9016-7B4D176AF315Q41247296-871D566A-75AC-4101-AB35-0E17263A956DQ41431279-413A369D-782D-43CD-8E18-40CAEBEBED4BQ41516708-240045DC-B4BB-426B-93EF-E62FA3F22F0AQ41704853-1BADC21E-EDF0-4966-8FE2-2DC777DEE887Q42405833-A1891671-3FE8-48F6-AC84-A053E129E8A4Q42614193-DFC077BB-002E-419E-B803-D673C8631F02Q42922583-1A9199A7-962C-4743-A080-32C262DC0FCBQ46787617-AB0ED2F6-7717-47C2-9764-F9FF06022D9DQ54098586-DC3365B2-41B5-4A00-8F08-533D52634CF7Q54415339-7B86078A-D52B-4C43-8F40-769F4C7AB61CQ58003631-362F65A5-578C-4C29-9A88-A361475D9CE6
P2860
Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 1985
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1).
@en
Erythromycin: a microbial and clinical perspective after 30 years of clinical use
@nl
type
label
Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1).
@en
Erythromycin: a microbial and clinical perspective after 30 years of clinical use
@nl
prefLabel
Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1).
@en
Erythromycin: a microbial and clinical perspective after 30 years of clinical use
@nl
P1476
Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1).
@en
P2093
J A Washington
W R Wilson
P304
P356
10.1016/S0025-6196(12)60219-5
P407
P577
1985-03-01T00:00:00Z